Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.

Potential genotoxic impurities in pharmaceuticals at trace levels are of increasing concern to both pharmaceutical industries and regulatory agencies due to their possibility for human carcinogenesis. Molecular functional groups that render starting materials and synthetic intermediates as reactive building blocks for small molecules may also be responsible for their genotoxicity. Determination of these genotoxic impurities at trace levels requires highly sensitive and selective analytical methodologies, which poses tremendous challenges on analytical communities in pharmaceutical research and development. Experimental guidance for the analytical determination of some important classes of genotoxic impurities is still unavailable in the literature. Therefore, the present review explores the structural alerts of commonly encountered potential genotoxic impurities, draft guidance of various regulatory authorities in order to control the level of impurities in drug substances and to assess their toxicity. This review also describes the analytical considerations for the determination of potential genotoxic impurities at trace levels and finally few case studies are also discussed for the determination of some important classes of potential genotoxic impurities. It is the authors' intention to provide a complete strategy that helps analytical scientists for the analysis of such potential genotoxic impurities in pharmaceuticals.

[1]  N. Venugopal,et al.  Method development and validation study for quantitative determination of 2-chloromethyl-3,4-dimethoxy pyridine hydrochloride a genotoxic impurity in pantoprazole active pharmaceutical ingredient (API) by LC/MS/MS. , 2012, Journal of pharmaceutical and biomedical analysis.

[2]  A. Antoccia,et al.  Genetic effects of petroleum fuels: cytogenetic monitoring of gasoline station attendants. , 1995, Mutation research.

[3]  T. Waegemaekers,et al.  Non-mutagenicity of 27 aliphatic acrylate esters in the Salmonella-microsome test. , 1984, Mutation research.

[4]  Lawrence X. Yu.  Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[5]  A. Vijaya Bhaskar Reddy,et al.  A selective and sensitive UPLC-MS/MS approach for trace level quantification of four potential genotoxic impurities in zolmitriptan drug substance. , 2013, Journal of pharmaceutical and biomedical analysis.

[6]  Q. Sui,et al.  Optimization of mobile phase for the determination of Esomeprazole and related compounds and investigation of stress degradation by LC-MS. , 2013, Journal of separation science.

[7]  P. Wei,et al.  Characterization of process-related impurities including forced degradation products of alogliptin benzoate and the development of the corresponding reversed-phase high-performance liquid chromatography method. , 2014, Journal of separation science.

[8]  R. Tennant,et al.  Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. , 1991, Mutation research.

[9]  Kelly Zhang,et al.  Analysis of pharmaceutical impurities using multi-heartcutting 2D LC coupled with UV-charged aerosol MS detection. , 2013, Journal of separation science.

[10]  F. Bouder.  Regulating impurities in pharmaceutical products: a tolerability of risk approach? , 2008, Expert review of clinical pharmacology.

[11]  Patrick Sandra,et al.  The utility of sulfonate salts in drug development. , 2010, Journal of pharmaceutical sciences.

[12]  D. Elder,et al.  Analytical approaches for the detection of epoxides and hydroperoxides in active pharmaceutical ingredients, drug products and herbals. , 2010, Journal of pharmaceutical and biomedical analysis.

[13]  Jan G Hengstler,et al.  Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. , 2004, Toxicology letters.

[14]  J W Green,et al.  A review of the genotoxicity of marketed pharmaceuticals. , 2001, Mutation research.

[15]  Richard P. Frost,et al.  Determination of pharmaceutical process impurities by solid phase microextraction gas chromatography , 2003 .

[16]  Naomi L Kruhlak,et al.  Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows Software to Achieve High-Performance, High-Confidence, Mode of Action–Based Predictions of Chemical Carcinogenesis in Rodents , 2008, Toxicology mechanisms and methods.

[17]  I. Abe,et al.  Determination of genotoxic phenylhydrazine agaritine in mushrooms using liquid chromatography–electrospray ionization tandem mass spectrometry , 2006, Food additives and contaminants.

[18]  D. Norwood,et al.  Genotoxic Impurities: A Quantitative Approach , 2008 .

[19]  Ronald D Snyder,et al.  An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity , 2009, Environmental and molecular mutagenesis.

[20]  S. Ohnishi,et al.  Oxidative DNA Damage Induced by a Metabolite of 2–Naphthylamine, a Smoking‐related Bladder Carcinogen , 2002, Japanese journal of cancer research : Gann.

[21]  Ronald D Snyder,et al.  Computational prediction of genotoxicity: room for improvement. , 2005, Drug discovery today.

[22]  Andrew Teasdale,et al.  A Tool for the Semiquantitative Assessment of Potentially Genotoxic Impurity (PGI) Carryover into API Using Physicochemical Parameters and Process Conditions , 2010 .

[23]  Vijay K Gombar,et al.  In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances. , 2010, Regulatory toxicology and pharmacology : RTP.

[24]  Krista L Dobo,et al.  Overview of Genotoxic Impurities in Pharmaceutical Development , 2009, International journal of toxicology.

[25]  David Q. Liu,et al.  A Systematic Method Development Strategy for Determination of Pharmaceutical Genotoxic Impurities , 2010 .

[26]  C. Welch,et al.  Chromatographic resolution of closely related species: drug metabolites and analogs. , 2014, Journal of separation science.

[27]  Yan Zhou,et al.  Optimisation of ultra-performance LC conditions using response surface methodology for rapid separation and quantitative determination of phenolic compounds in Artemisia minor. , 2010, Journal of separation science.

[28]  A. Vijaya Bhaskar Reddy,et al.  Trace level quantification of 1-(3-chloropropyl)-4-(3-chlorophenyl)piperazine HCl genotoxic impurity in trazodone using LC–MS/MS , 2014, Arabian Journal of Chemistry.

[29]  Xi-jun Wang,et al.  Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies. , 2011, Journal of separation science.

[30]  K. Ramakrishna,et al.  Development and validation of GC-MS method for the determination of methyl methanesulfonate and ethyl methanesulfonate in imatinib mesylate. , 2008, Journal of pharmaceutical and biomedical analysis.

[31]  David Q. Liu,et al.  Matrix deactivation: A general approach to improve stability of unstable and reactive pharmaceutical genotoxic impurities for trace analysis. , 2010, Journal of pharmaceutical and biomedical analysis.

[32]  C. Humfrey.  Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[33]  Roman Szucs,et al.  A generic approach for the determination of residues of alkylating agents in active pharmaceutical ingredients by in situ derivatization-headspace-gas chromatography-mass spectrometry. , 2007, Journal of pharmaceutical and biomedical analysis.

[34]  R. Tennant,et al.  Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. , 1988, Mutation research.

[35]  Zadeo Cimarosti,et al.  Application of Quality by Design Principles to Support Development of a Control Strategy for the Control of Genotoxic Impurities in the Manufacturing Process of a Drug Substance , 2010 .

[36]  David Q. Liu,et al.  Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process. , 2009, Journal of pharmaceutical and biomedical analysis.

[37]  Andrew Teasdale,et al.  Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control , 2013 .

[38]  David L. Varie,et al.  Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug Substances , 2009 .

[39]  Low level determination of 4-amino-2-ethoxy-cinnamic acid and its ethyl ester in a drug substance and its formulation prototypes by HPLC-UV-DAD. , 2009, Journal of chromatographic science.

[40]  Janice M Fiori,et al.  Extending the threshold of regulation concept: de minimis limits for carcinogens and mutagens. , 2002, Regulatory toxicology and pharmacology : RTP.

[41]  David Q. Liu,et al.  A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances. , 2008, Journal of pharmaceutical and biomedical analysis.

[42]  Hong Zhang,et al.  Determination of marker residue of Olaquindox in fish tissue by ultra performance liquid chromatography-tandem mass spectrometry. , 2011, Journal of separation science.

[43]  L. Hall,et al.  Three new consensus QSAR models for the prediction of Ames genotoxicity. , 2004, Mutagenesis.

[44]  E. G. Lovering,et al.  Determination of hydrazine in pharmaceuticals III: hydralazine and isoniazid using GLC. , 1983, Journal of pharmaceutical sciences.

[45]  Lutz Müller,et al.  A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. , 2006, Regulatory toxicology and pharmacology : RTP.

[46]  J. Wolff,et al.  Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API). , 2008, Journal of pharmaceutical and biomedical analysis.

[47]  P. K. Basniwal,et al.  Forced degradation and impurity profiling: recent trends in analytical perspectives. , 2013, Journal of pharmaceutical and biomedical analysis.

[48]  N Flamand,et al.  Mini mutagenicity test: a miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[49]  Zhong-Zhen Zhao,et al.  Determination of glucosinolates in traditional Chinese herbs by high-performance liquid chromatography and electrospray ionization mass spectrometry , 2006, Analytical and bioanalytical chemistry.

[50]  K. Ramakrishna,et al.  Development and validation of LC methods with visible detection using pre-column derivatization and mass detection for the assay of voglibose. , 2009, Talanta.

[51]  J. Aubrecht,et al.  Genotoxicity profiles of common alkyl halides and esters with alkylating activity. , 2007, Mutation research.

[52]  Naomi L Kruhlak,et al.  Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. , 2007, Advanced drug delivery reviews.

[53]  David Q. Liu,et al.  A generic approach for the determination of trace hydrazine in drug substances using in situ derivatization-headspace GC-MS. , 2009, Journal of pharmaceutical and biomedical analysis.

[54]  S. Boyer,et al.  The incidence of positive results in the mouse lymphoma TK assay (MLA) in pharmaceutical screening and their prediction by MultiCase MC4PC. , 2011, Mutagenesis.

[55]  David Q. Liu,et al.  Enhancing the detection sensitivity of trace analysis of pharmaceutical genotoxic impurities by chemical derivatization and coordination ion spray-mass spectrometry. , 2010, Journal of chromatography. A.

[56]  T. McGovern,et al.  Toxicological overview of impurities in pharmaceutical products. , 2007, Advanced drug delivery reviews.

[57]  J J DeGeorge,et al.  Changes to ICH Guideline M3: New and Revised Guidance on Nonclinical Safety Studies to Support Human Clinical Trials and Marketing Authorization , 2011, Clinical pharmacology and therapeutics.

[58]  J. Klimeš,et al.  HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers. , 2008, Journal of pharmaceutical and biomedical analysis.

[59]  A. Krstulović,et al.  Determination of N,N-dimethylaminoethyl chloride and the dimethylaziridinium ion at sub-ppm levels in diltiazem hydrochloride by LC-MS with electrospray ionisation. , 2000, The Analyst.

[60]  Nigel Greene,et al.  The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. , 2006, Regulatory toxicology and pharmacology : RTP.

[61]  R. Snyder,et al.  Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules , 2004, Environmental and molecular mutagenesis.

[62]  D. E. Patterson,et al.  Development of a Practical Large-Scale Synthesis of Denagliptin Tosylate , 2009 .

[63]  B H Margolin,et al.  Predicting rodent carcinogenicity from mutagenic potency measured in the Ames Salmonella assay , 1997, Environmental and molecular mutagenesis.

[64]  D. Snodin.  Genotoxic Impurities: From Structural Alerts to Qualification , 2010 .

[65]  C. Riley,et al.  Prediction of Drug Degradation Pathways leading to Structural Alerts for Potential Genotoxic Impurities , 2010 .

[66]  D. Elder,et al.  Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. , 2011, Journal of pharmaceutical and biomedical analysis.

[67]  David Q. Liu,et al.  Recent advances in trace analysis of pharmaceutical genotoxic impurities. , 2010, Journal of pharmaceutical and biomedical analysis.

[68]  H S Rosenkranz,et al.  Identification of 'genotoxic' and 'non-genotoxic' alerts for cancer in mice: the carcinogenic potency database. , 1998, Mutation research.

[69]  E. Wang,et al.  Detection of hydrazine, methylhydrazine, and isoniazid by capillary electrophoresis with a palladium-modified microdisk array electrode. , 1996, Analytical chemistry.

[70]  A. Viksna,et al.  Application of hydrophilic interaction chromatography for simultaneous separation of six impurities of mildronate substance. , 2008, Journal of pharmaceutical and biomedical analysis.

[71]  J. Vessman,et al.  Determination of hydrazine in hydralazine by capillary gas chromatography with nitrogen-selective detection after benzaldehyde derivatization. , 1990, Journal of Chromatography A.

[72]  K. Gates,et al.  DNA binding and alkylation by the "left half" of azinomycin B. , 2000, Biochemistry.

[73]  Warren W Ku,et al.  An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities. , 2007, Regulatory toxicology and pharmacology : RTP.

[74]  M Vijayaraj Reddy,et al.  Genotoxicity of benzene and its metabolites. , 2004, Mutation research.

[75]  Y. Vander Heyden,et al.  Method development for HILIC assays. , 2008, Journal of separation science.

[76]  K. Ramakrishna,et al.  Development and validation of RP-HPLC method for the determination of genotoxic alkyl benzenesulfonates in amlodipine besylate. , 2008, Journal of pharmaceutical and biomedical analysis.

[77]  Derek Robinson,et al.  Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective , 2010 .

[78]  D. Elder,et al.  Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs). , 2008, Journal of pharmaceutical and biomedical analysis.

[79]  Haiyu Xu,et al.  Chemical fingerprint analysis of Phellodendri Amurensis Cortex by ultra performance LC/Q-TOF-MS methods combined with chemometrics. , 2010, Journal of separation science.

[80]  Zhigang Hao,et al.  Impact of column temperature and mobile phase components on selectivity of hydrophilic interaction chromatography (HILIC). , 2008, Journal of separation science.

[81]  D. Elder,et al.  Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs). , 2008, Journal of pharmaceutical and biomedical analysis.

[82]  R. N. Rao,et al.  Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS. , 2008, Journal of separation science.

[83]  A. Vijaya Bhaskar Reddy,et al.  A selective and sensitive LC-MS/MS method for the simultaneous determination of twopotential genotoxic impurities in celecoxib , 2014, Journal of Analytical Science and Technology.

[84]  A. Vijaya Bhaskar Reddy,et al.  Development and validation of a systematic UPLC-MS/MS method for simultaneous determination of three phenol impurities in ritonavir. , 2014, Journal of pharmaceutical and biomedical analysis.

[85]  R. Ogilvie,et al.  Acceptability of Low Levels of Genotoxic Impurities in New Drug Substances , 2012, International Journal of Pharmaceutical Medicine.